文献速递泌尿生殖技术与安全PETCT

PSMA PET/CT衍生的肿瘤体积预测接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者的结局

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
PubMed 文献 · Radiology · 2026-01-01

本研究在168例接受Lu-PSMA治疗的mCRPC患者中外部验证了既往预测模型,并评估总肿瘤体积(TTV)的增量价值。将二分类转移灶数目替换为TTV后,总生存的C指数提高0.04(95%CI:0.01,0.07;P=0.002),且TTV与更短的总生存和PSA无进展生存相关。

要点

  • TTV可替代二分类转移灶数目以提升总生存预测的区分度(C指数提高0.04)。
  • 较高的TTV与更短的总生存和PSA无进展生存相关,并与更低的PSA50相关。
  • 二分类转移灶数目与总生存无独立关联证据(HR 1.23,95%CI:0.64,2.36;P=0.53)。

核心结论

  • 既往开发的模型可预测接受Lu-PSMA治疗的mCRPC患者的总生存、PSA无进展生存和PSA50;纳入TTV的预测模型较二分类或连续转移灶数目具有更好的区分能力。

研究设计与样本

  • 外部验证研究,纳入2022年6月至2024年4月期间接受Lu-PSMA治疗的患者168例(中位年龄73岁,IQR 68-78岁),以基线变量构建的既往模型进行外部验证。

诊断标准与关键数值

  • 原模型外部验证C指数:总生存0.70(95%CI:0.64,0.77),PSA无进展生存0.68(95%CI:0.63,0.73),PSA50为0.72(95%CI:0.64,0.80)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Accurate prediction of the response of patients with metastatic castration-resistant prostate cancer (mCRPC) to lutetium 177 prostate-specific membrane antigen-617 (Lu-PSMA) therapy would be helpful for treatment selection. Purpose To evaluate the incremental value of total tumor volume (TTV) in prediction models developed for patients receiving Lu-PSMA. Materials and Methods Previously developed prediction models using baseline variables (time since diagnosis, chemotherapy status, hemoglobin, dichotomized number of metastases, tumor mean standardized uptake value, and bone and liver involvement) were externally validated in patients treated with Lu-PSMA between June 2022 and April 2024. The concordance index (ie, C index) for overall survival (OS), prostate-specific antigen (PSA) progression-free survival (PSA-PFS), and 50% or greater decline in PSA from baseline (PSA50) was assessed. The predictive value of prostate-specific membrane antigen PET/CT-derived TTV was evaluated by re-estimating previous models (Cox regression for OS and PSA-PFS; logistic regression for PSA50) and replacing the dichotomized number of metastases with the continuous number of metastases or TTV. Results Data from 168 patients (median age, 73 years [IQR, 68-78 years]) were analyzed. External validation of the original models achieved C indexes of 0.70 (95% CI: 0.64, 0.77) for OS, 0.68 (95% CI: 0.63, 0.73) for PSA-PFS, and 0.72 (95% CI: 0.64, 0.80) for PSA50. Replacing the dichotomized number of metastases with TTV increased the C index for OS by 0.04 (95% CI: 0.01, 0.07; P = .002). A higher TTV was associated with shorter OS (hazard ratio, 1.35 [95% CI: 1.08, 1.68]), whereas there was no evidence of an independent association between dichotomized number of metastases and OS (hazard ratio, 1.23 [95% CI: 0.64, 2.36]; P = .53). A higher TTV was associated with shorter PSA-PFS (hazard ratio, 1.25 [95% CI: 1.10, 1.42]) and lower PSA50 (odds ratio, 0.70 [95% CI: 0.53, 0.91]). Conclusion Previously developed models predicted OS, PSA-PFS, and PSA50 in patients with mCRPC receiving Lu-PSMA. The inclusion of TTV produces prediction models with better discriminatory ability than the dichotomized or continuous number of metastases. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Vargas and Woo in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ghodsi A, Owens L, Demirci RA, et al. PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617. Radiology. 2026. PMID: 41914866. doi:10.1148/radiol.250649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。